Pancreatic Cancer Research

ResearcherConsejo Superior de Investigaciones CientíficasNo recent work listed

Sladjana Zagorac

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6389-1830; OpenAlex author ID A5017704416. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers

Papers 7

  1. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biopha.2022.114162↗
  2. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  3. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  4. Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-019-11752-2↗
  5. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Co-author DOI 10.1038/s41467-018-03962-x↗
  6. DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. Co-author DOI 10.1158/0008-5472.can-15-3268↗
  7. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Co-author DOI 10.1016/j.stem.2011.10.001↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher Heeschen · 5 shared papers, 2011–2023 · strength 0.39
  2. Anna Melissa Schlitter · 2 shared papers, 2021–2023 · strength 0.22
  3. Álvaro Curiel‐García · 1 shared paper, 2023 · strength 0.18
  4. Sarah Courtois · 1 shared paper, 2023 · strength 0.18
  5. Patricia Sancho Andrés · 1 shared paper, 2023 · strength 0.18
  6. Beatriz Parejo-Alonso · 1 shared paper, 2023 · strength 0.18
  7. Pilar Espiau-Romera · 1 shared paper, 2023 · strength 0.18
  8. Kenneth P. Olive · 1 shared paper, 2023 · strength 0.18
  9. Sonia Alcalá · 3 shared papers, 2011–2021 · strength 0.16
  10. Bruno Sáinz · 2 shared papers, 2016–2021 · strength 0.14
  11. Justin Stebbing · 2 shared papers, 2018–2019 · strength 0.14
  12. Leandro Castellano · 2 shared papers, 2018–2019 · strength 0.14
  13. Sara Maria David Trabulo · 2 shared papers, 2018–2019 · strength 0.14
  14. Niccola Funel · 2 shared papers, 2018–2019 · strength 0.14
  15. Silvia Ottaviani · 2 shared papers, 2018–2019 · strength 0.14
  16. Jonathan Krell · 2 shared papers, 2018–2019 · strength 0.14
  17. Long R. Jiao · 2 shared papers, 2018–2019 · strength 0.14
  18. Elisa Giovannetti · 2 shared papers, 2018–2019 · strength 0.14
  19. Adam Enver Frampton · 2 shared papers, 2018–2019 · strength 0.14
  20. Thomas Mathias Gress · 2 shared papers, 2018–2019 · strength 0.14
  21. Wilko Weichert · 1 shared paper, 2023 · strength 0.13
  22. Irene Felipe‐Abrio · 1 shared paper, 2023 · strength 0.13
  23. Thomas Knösel · 1 shared paper, 2023 · strength 0.13
  24. Paula Ghaneh · 1 shared paper, 2023 · strength 0.13
  25. Daniel H. Palmer · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.